Immunovant reports ~80% response and 50% ATD-free remission in Graves' disease trial at six months off-treatment

Immunovant, Inc.

80% (17/21) of uncontrolled Graves' patients maintained normal thyroid function six months after stopping batoclimab.
50% (8/17) of responders achieved anti-thyroid drug-free remission at six months off-treatment.
Two registrational trials for lead compound IMVT-1402 in Graves' disease are enrolling with topline data expected in 2027.
Immunovant will host an investor call on September 3, 2025, at 4:30 p.m. EDT to discuss the data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.